Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Structure-based discovery of cytotoxic dimeric tetrahydroxanthones as potential topoisomerase I inhibitors from a marine-derived fungus.

Wu G, Qi X, Mo X, Yu G, Wang Q, Zhu T, Gu Q, Liu M, Li J, Li D.

Eur J Med Chem. 2018 Mar 25;148:268-278. doi: 10.1016/j.ejmech.2018.02.041. Epub 2018 Feb 13.

PMID:
29466776
2.

Versixanthones A-F, Cytotoxic Xanthone-Chromanone Dimers from the Marine-Derived Fungus Aspergillus versicolor HDN1009.

Wu G, Yu G, Kurtán T, Mándi A, Peng J, Mo X, Liu M, Li H, Sun X, Li J, Zhu T, Gu Q, Li D.

J Nat Prod. 2015 Nov 25;78(11):2691-8. doi: 10.1021/acs.jnatprod.5b00636. Epub 2015 Oct 27.

PMID:
26506221
3.

Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.

Xin LT, Liu L, Shao CL, Yu RL, Chen FL, Yue SJ, Wang M, Guo ZL, Fan YC, Guan HS, Wang CY.

Mar Drugs. 2017 Jul 9;15(7). pii: E217. doi: 10.3390/md15070217.

4.

Synthesis of novel benzoxanthone analogues as non-Camptothecin topoisomerase I inhibitors.

Cheng P, Zhu L, Guo W, Liu W, Yao J, Dong G, Zhang Y, Zhuang C, Sheng C, Miao Z, Zhang W.

J Enzyme Inhib Med Chem. 2012 Jun;27(3):437-42. doi: 10.3109/14756366.2011.595712. Epub 2011 Jul 20.

PMID:
21770860
5.

Secalonic acid D as a novel DNA topoisomerase I inhibitor from marine lichen-derived fungus Gliocladium sp. T31.

Hong R.

Pharm Biol. 2011 Aug;49(8):796-9. doi: 10.3109/13880209.2010.548817. Epub 2011 Apr 15.

PMID:
21495809
6.

Cytotoxic Tetrahydroxanthone Dimers from the Mangrove-Associated Fungus Aspergillus versicolor HDN1009.

Yu G, Wu G, Sun Z, Zhang X, Che Q, Gu Q, Zhu T, Li D, Zhang G.

Mar Drugs. 2018 Sep 14;16(9). pii: E335. doi: 10.3390/md16090335.

7.

Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.

Jun KY, Lee EY, Jung MJ, Lee OH, Lee ES, Park Choo HY, Na Y, Kwon Y.

Eur J Med Chem. 2011 Jun;46(6):1964-71. doi: 10.1016/j.ejmech.2011.01.011. Epub 2011 Jan 15.

PMID:
21419530
8.

Novel securinine derivatives as topoisomerase I based antitumor agents.

Hou W, Wang ZY, Peng CK, Lin J, Liu X, Chang YQ, Xu J, Jiang RW, Lin H, Sun PH, Chen WM.

Eur J Med Chem. 2016 Oct 21;122:149-163. doi: 10.1016/j.ejmech.2016.06.021. Epub 2016 Jun 15.

PMID:
27344492
9.

Unusual dimeric tetrahydroxanthone derivatives from Aspergillus lentulus and the determination of their axial chiralities.

Li TX, Yang MH, Wang Y, Wang XB, Luo J, Luo JG, Kong LY.

Sci Rep. 2016 Dec 12;6:38958. doi: 10.1038/srep38958.

10.

Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.

My Van HT, Woo H, Jeong HM, Khadka DB, Yang SH, Zhao C, Jin Y, Lee ES, Youl Lee K, Kwon Y, Cho WJ.

Eur J Med Chem. 2014 Jul 23;82:181-94. doi: 10.1016/j.ejmech.2014.05.047. Epub 2014 May 21.

PMID:
24904965
11.

Modification of 3-arylisoquinolines into 3,4-diarylisoquinolines and assessment of their cytotoxicity and topoisomerase inhibition.

Khadka DB, Woo H, Yang SH, Zhao C, Jin Y, Le TN, Kwon Y, Cho WJ.

Eur J Med Chem. 2015 Mar 6;92:583-607. doi: 10.1016/j.ejmech.2015.01.016. Epub 2015 Jan 14.

PMID:
25613224
12.

Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.

Xu Y, Wu L, Rashid HU, Jing D, Liang X, Wang H, Liu X, Jiang J, Wang L, Xie P.

Eur J Med Chem. 2018 Aug 5;156:479-492. doi: 10.1016/j.ejmech.2018.07.028. Epub 2018 Jul 17.

PMID:
30025344
13.

Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.

Khadka DB, Park S, Jin Y, Han J, Kwon Y, Cho WJ.

Eur J Med Chem. 2018 Jan 1;143:200-215. doi: 10.1016/j.ejmech.2017.11.011. Epub 2017 Nov 7.

PMID:
29174815
14.

Antibacterial anthraquinone dimers from marine derived fungus Aspergillus sp.

Li JL, Jiang X, Liu X, He C, Di Y, Lu S, Huang H, Lin B, Wang D, Fan B.

Fitoterapia. 2019 Mar;133:1-4. doi: 10.1016/j.fitote.2018.11.015. Epub 2018 Dec 10.

PMID:
30543983
15.

Design, synthesis, cytotoxic activity and molecular docking studies of new 20(S)-sulfonylamidine camptothecin derivatives.

Song ZL, Wang MJ, Li L, Wu D, Wang YH, Yan LT, Morris-Natschke SL, Liu YQ, Zhao YL, Wang CY, Liu H, Goto M, Liu H, Zhu GX, Lee KH.

Eur J Med Chem. 2016 Jun 10;115:109-20. doi: 10.1016/j.ejmech.2016.02.070. Epub 2016 Mar 3.

16.

3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.

Park SE, Chang IH, Jun KY, Lee E, Lee ES, Na Y, Kwon Y.

Eur J Med Chem. 2013 Nov;69:139-45. doi: 10.1016/j.ejmech.2013.07.048. Epub 2013 Aug 11.

PMID:
24013413
17.

Synthesis of new xanthone analogues and their biological activity test--cytotoxicity, topoisomerase II inhibition, and DNA cross-linking study.

Woo S, Jung J, Lee C, Kwon Y, Na Y.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1163-6. Epub 2006 Dec 13.

PMID:
17194586
18.

Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.

Ahmad P, Woo H, Jun KY, Kadi AA, Abdel-Aziz HA, Kwon Y, Rahman AF.

Bioorg Med Chem. 2016 Apr 15;24(8):1898-908. doi: 10.1016/j.bmc.2016.03.017. Epub 2016 Mar 8.

PMID:
26988802
19.

Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents.

Thapa P, Kadayat TM, Park S, Shin S, Thapa Magar TB, Bist G, Shrestha A, Na Y, Kwon Y, Lee ES.

Bioorg Chem. 2016 Jun;66:145-59. doi: 10.1016/j.bioorg.2016.04.007. Epub 2016 Apr 28.

PMID:
27174797
20.

Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors.

Zhang C, Li S, Ji L, Liu S, Li Z, Li S, Meng X.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4693-6. doi: 10.1016/j.bmcl.2015.06.042. Epub 2015 Jun 26.

PMID:
26384290

Supplemental Content

Support Center